Compare Stryker Corporation (SYK) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Stryker Corporation trades at $276.3 (market cap $106.03B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.2. The key difference: Stryker Corporation pays a 1.27% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.
| SYK | YMAG | |
|---|---|---|
Market Cap | $106.03B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $388.79 | $15.98 |
52-Week Low | $275.39 | $10.76 |
Enterprise Value | $117.50B | — |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
YMAG trades at $11.26, down slightly (-0.18%) on the day. The technical outlook is bullish with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.07 to $0.11 per share. Recent news highlights YieldMax's ongoing distribution announcements and trading activity, with the stock showing 2.7% gains in recent sessions according to Defense World (August 4, 2026).
The outlook remains positive given the bullish technical signals and consistent income generation through dividends. However, investors should monitor NAV stability during earnings periods as noted by Seeking Alpha (July 28, 2026). Key risks include option strategy execution and market volatility affecting the underlying Magnificent 7 components. The ETF's performance remains tied to successful option income generation and component stock stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
